D. Carbone

693 total citations
15 papers, 530 citations indexed

About

D. Carbone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, D. Carbone has authored 15 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in D. Carbone's work include Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). D. Carbone is often cited by papers focused on Lung Cancer Research Studies (6 papers), Lung Cancer Treatments and Mutations (6 papers) and Lung Cancer Diagnosis and Treatment (4 papers). D. Carbone collaborates with scholars based in United States, France and Germany. D. Carbone's co-authors include Jay A. Berzofsky, I. Frank Ciernik, John D. Minna, Taku Tsukui, C D Pendleton, Scott F. Winter, Adi F. Gazdar, Bruce E. Johnson, J D Minna and Sebastian Winter and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Hepatology.

In The Last Decade

D. Carbone

15 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Carbone United States 9 261 231 230 76 65 15 530
Gina Choe United States 8 353 1.4× 158 0.7× 193 0.8× 44 0.6× 40 0.6× 11 566
Nathalie Baudson Belgium 11 189 0.7× 269 1.2× 171 0.7× 50 0.7× 86 1.3× 19 520
H. A. Turchin United States 9 147 0.6× 134 0.6× 163 0.7× 110 1.4× 22 0.3× 15 496
Jana Šímová Czechia 15 533 2.0× 269 1.2× 231 1.0× 30 0.4× 109 1.7× 63 723
Johannes Laengle Austria 12 183 0.7× 227 1.0× 181 0.8× 55 0.7× 45 0.7× 25 505
Mara Valentini Italy 5 450 1.7× 379 1.6× 125 0.5× 38 0.5× 44 0.7× 5 643
I Joyeux France 7 406 1.6× 306 1.3× 117 0.5× 31 0.4× 45 0.7× 9 568
Tyler Walther United States 3 199 0.8× 317 1.4× 116 0.5× 58 0.8× 30 0.5× 4 473
György Stuber Sweden 14 468 1.8× 334 1.4× 149 0.6× 31 0.4× 141 2.2× 22 716
R Brew United Kingdom 10 303 1.2× 224 1.0× 155 0.7× 22 0.3× 35 0.5× 16 579

Countries citing papers authored by D. Carbone

Since Specialization
Citations

This map shows the geographic impact of D. Carbone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Carbone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Carbone more than expected).

Fields of papers citing papers by D. Carbone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Carbone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Carbone. The network helps show where D. Carbone may publish in the future.

Co-authorship network of co-authors of D. Carbone

This figure shows the co-authorship network connecting the top 25 collaborators of D. Carbone. A scholar is included among the top collaborators of D. Carbone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Carbone. D. Carbone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Bittoni, Marisa A., D. Carbone, & Randall E. Harris. (2024). Vaping, Smoking and Lung Cancer Risk. PubMed. 9(3). 10 indexed citations
2.
3.
Patel, Jyoti D., Henry Wagner, D. Carbone, et al.. (2018). MA05.01 E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC. Journal of Thoracic Oncology. 13(10). S370–S370. 1 indexed citations
4.
Miller, Eric D., James L. Fisher, Kaisa Haglund, et al.. (2018). Racial/Ethnic Disparities in the Delivery of Curative Intent Therapy in Patients with Stage III Non-small Cell Lung Cancer Not Treated Surgically: An Analysis of the National Cancer Database. International Journal of Radiation Oncology*Biology*Physics. 102(3). e410–e410. 1 indexed citations
5.
Solomon, Brad, Vanesa Gregorc, Kazuo Kasahara, et al.. (2006). Prediction of clinical outcome in non-small cell lung cancer (NSCLC) patients treated with gefitinib using Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) of serum. Journal of Clinical Oncology. 24(18_suppl). 7004–7004. 3 indexed citations
6.
Kris, Mark G., V. A. Miller, William Pao, et al.. (2005). EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. Journal of Clinical Oncology. 23(16_suppl). 7029–7029. 21 indexed citations
7.
Kris, Mark G., V.A. Miller, D. Carbone, et al.. (2005). O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma. Lung Cancer. 49. S38–S39. 7 indexed citations
8.
Gandara, David R., Everett E. Vokes, Philip Bonomi, et al.. (1997). 72 Multicenter trial of docetaxel (Taxotere) in platinum-treated non-small cell lung cancer (NSCLC): Confirmation of prolonged survival. Lung Cancer. 18. 21–21. 18 indexed citations
9.
Ciernik, I. Frank, Jay A. Berzofsky, & D. Carbone. (1996). Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. The Journal of Immunology. 156(7). 2369–2375. 150 indexed citations
10.
Ciernik, I. Frank, et al.. (1995). Expression of transforming growth factor beta and transforming growth factor beta receptors on AIDS-associated Kaposi's sarcoma.. PubMed. 1(10). 1119–24. 13 indexed citations
11.
Winter, Sebastian, Yoshitaka Sekido, J D Minna, et al.. (1993). Antibodies Against Autologous Tumor Cell Proteins in Patients With Small-Cell Lung Cancer: Association With Improved Survival. JNCI Journal of the National Cancer Institute. 85(24). 2012–2018. 81 indexed citations
12.
Carbone, D., C D Pendleton, Taku Tsukui, et al.. (1993). A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.. PubMed. 53(14). 3257–61. 135 indexed citations
13.
D’Amico, Domenico, et al.. (1993). Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer. Lung Cancer. 8(5-6). 337–337. 28 indexed citations
14.
Carbone, D., et al.. (1991). Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology.. PubMed. 51(22). 6142–9. 49 indexed citations
15.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gina Choe Breakdown of academic impact, for papers by Nathalie Baudson Breakdown of academic impact, for papers by H. A. Turchin Breakdown of academic impact, for papers by Jana Šímová Breakdown of academic impact, for papers by Johannes Laengle Breakdown of academic impact, for papers by Mara Valentini Breakdown of academic impact, for papers by I Joyeux Breakdown of academic impact, for papers by Tyler Walther Breakdown of academic impact, for papers by György Stuber Breakdown of academic impact, for papers by R Brew
Rankless by CCL
2026